ctDNA MRD Monitoring

About Exact Sciences

Exact Sciences is a $20+ billion market cap leader in cancer diagnostics, driven by a mission to prevent, detect earlier, and guide treatment for cancer. Its success is anchored by the dominant Cologuard® colorectal cancer screening test and the globally recognized Oncotype DX® genomic test suite. The company's strategy focuses on expanding its integrated oncology portfolio, notably through the launch of its multi-cancer early detection test, CancerGuard™, and leveraging strategic partnerships like the one with Abbott for enhanced global scale. This positions Exact Sciences to address the full cancer care continuum from screening to treatment guidance.

Therapeutic Areas